Tumor Immunology and Immunotherapy Program

14.0摘要：肿瘤免疫学和免疫治疗(TII)计划 TII计划是一个跨学科的计划，致力于高度创新的基础科学研究和 转化性/临床试验。TII计划的总体目标是开发和实施基于免疫的 监测和治疗癌症的战略。为了实现这一目标，该计划侧重于三个研究目标：目标1： 以细胞为基础和调节途径为靶向的癌症免疫疗法--发展基于细胞和调节的免疫疗法 针对途径的癌症免疫疗法，能够减少或监测恶性细胞的生长。 目标2：调整免疫调节-制定克服肿瘤引起的免疫抑制的策略 并减轻免疫治疗相关的不良反应。目标3：癌症与炎症--阐明它们的作用 感染和炎症反应在癌症发展中的作用。TII项目是一项跨学科的研究 和教育项目。项目成员致力于了解恶性肿瘤的免疫调节。 并将这一知识转化为新的诊断和治疗方案的开发。这个 TII计划有35名成员，其中18名是正式成员，17名是准成员，他们从事癌症- 重点研究得到1660万美元的年度直接成本资助(总计2170万美元)，包括190万美元 (11.2%)来自NCI，1050万美元来自其他同行审查来源。TII计划成员获得430万美元 每年来自非同行审查的资金来源。在这一资助期间，TII成员创作了371 与癌症有关的出版物，其中15%来自方案内，30%来自方案间，以及 6%来自计划内和计划间合作；%的出版物包括与外部的合作 调查人员，反映了TII计划在全国的高度影响，14%的TII出版物是在期刊上发表的 影响因子为≥10。TII教职员工的研究工作得到了所有共享 服务。TII计划与马里兰大学的其他研究计划相结合 和斯图尔特·格林鲍姆综合癌症中心(UMGCCC)和TII与社区互动 外展和参与(COE)作为确定我们集水区社区需求的桥梁。

14.0 Abstract: Tumor Immunology and Immunotherapy (TII) Program The TII Program is an interdisciplinary program that pursues highly innovative basic science research and translational/clinical trials. The overall goal of the TII Program is to develop and implement immune-based strategies to monitor and treat cancer. To achieve this goal, the program focuses on three research aims: Aim 1: Cell-based and regulatory pathway-targeted cancer immunotherapies—Develop cell-based and regulatory pathway-targeted cancer immunotherapies that are capable of reducing or monitoring malignant cell growth. Aim 2: Calibrating immune regulation—Develop strategies to overcome tumor-induced immunosuppression and to mitigate immunotherapy-related adverse effects. Aim 3: Cancer and inflammation—Elucidate the roles of infection and inflammatory responses in cancer development. The TII Program is an interdisciplinary research and educational program. Program members are dedicated to understanding the immune regulation of malignant disease and translating this knowledge into the development of novel diagnostic and treatment regimens. The TII Program has 35 members, including 18 full members and 17 associate members, who conduct cancer- focused research supported by $16.6 million annual direct cost funding ($21.7 million total), including $1.9 million (11.2%) from NCI and $10.5 million from other peer-reviewed sources. TII Program members receive $4.3 million annually from non–peer-reviewed funding sources. During this funding period, TII members authored 371 cancer-related publications, of which 15% resulted from intraprogrammatic, 30% from interprogrammatic, and 6% from intra and interprogrammatic collaborations; 64% of publications include collaborations with external investigators, reflecting the high national impact of the TII Program, and 14% of TII publications were in journals with an impact factor ≥10. The research efforts of TII faculty are supported by extensive use of all shared services. The TII Program is integrated with the other research programs at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) and TII interacts with Community Outreach and Engagement (COE) as a bridge to identify the needs of communities in our catchment area.